Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Ashton

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
DNA Repair|January 15, 2010
Yeast as a model system to study RecQ helicase functionThomas M Ashton, Ian D Hickson
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2011
Holliday junction-containing DNA structures persist in cells lacking Sgs1 or Top3 following exposure to DNA damageHocine W Mankouri, Thomas M Ashton, Ian D Hickson
Cell Death & Disease|October 26, 2018
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeuticsKatharine J Herbert, Thomas M Ashton, Remko Prevo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Oxidative Phosphorylation as an Emerging Target in Cancer TherapyThomas M Ashton, W Gillies McKenna, Leoni A Kunz-Schughart, et al.
Molecular and Cellular Biology|February 24, 2011
Pathways for Holliday junction processing during homologous recombination in Saccharomyces cerevisiaeThomas M Ashton, Hocine W Mankouri, Anna Heidenblut, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2014
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxiaCatherine J Kelly, Kamila Hussien, Emmanouil Fokas, et al.
British Journal of Cancer|July 6, 2017
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapyGiacomo Pirovano, Thomas M Ashton, Katharine J Herbert, et al.
Nature Communications|July 26, 2016
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxiaThomas M Ashton, Emmanouil Fokas, Leoni A Kunz-Schughart, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
DNA Repair|January 15, 2010
Yeast as a model system to study RecQ helicase functionThomas M Ashton, Ian D Hickson
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2011
Holliday junction-containing DNA structures persist in cells lacking Sgs1 or Top3 following exposure to DNA damageHocine W Mankouri, Thomas M Ashton, Ian D Hickson
Cell Death & Disease|October 26, 2018
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeuticsKatharine J Herbert, Thomas M Ashton, Remko Prevo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Oxidative Phosphorylation as an Emerging Target in Cancer TherapyThomas M Ashton, W Gillies McKenna, Leoni A Kunz-Schughart, et al.
Molecular and Cellular Biology|February 24, 2011
Pathways for Holliday junction processing during homologous recombination in Saccharomyces cerevisiaeThomas M Ashton, Hocine W Mankouri, Anna Heidenblut, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2014
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxiaCatherine J Kelly, Kamila Hussien, Emmanouil Fokas, et al.
British Journal of Cancer|July 6, 2017
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapyGiacomo Pirovano, Thomas M Ashton, Katharine J Herbert, et al.
Nature Communications|July 26, 2016
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxiaThomas M Ashton, Emmanouil Fokas, Leoni A Kunz-Schughart, et al.
Pageof 1